Large scale production of a mammalian cell derived quadrivalent hepatitis C virus like particle vaccine

L Earnest-Silveira; D Christiansen; S Herrmann; SA Ralph; S Das; EJ Gowans; J Torresi

Journal article

Large scale production of a mammalian cell derived quadrivalent hepatitis C virus like particle vaccine

L Earnest-Silveira, D Christiansen, S Herrmann, SA Ralph, S Das, EJ Gowans, J Torresi

Journal of Virological Methods | ELSEVIER SCIENCE BV | Published : 2016

DOI: 10.1016/j.jviromet.2016.06.012

Abstract

A method for the large-scale production of a quadrivalent mammalian cell derived hepatitis C virus-like particles (HCV VLPs) is described. The HCV core E1 and E2 coding sequences of genotype 1a, 1b, 2a or 3a were co-expressed in Huh7 cell factories using a recombinant adenoviral expression system. The structural proteins self-assembled into VLPs that were purified from Huh7 cell lysates by iodixanol ultracentrifugation and Stirred cell ultrafiltration. Electron microscopy, revealed VLPs of the different genotypes that are morphologically similar. Our results show that it is possible to produce large quantities of individual HCV genotype VLPs with relative ease thus making this approach an al..

View full abstract

University of Melbourne Researchers

Linda Earnest Author

Stuart Ralph Author

Joseph Torresi Author

Related Projects (3)

CELL BIOLOGY OF MALARIA PARASITES

I am a molecular biologist and bioinformatician studying the cell biology of human parasites. I have expertise in the bioinformatic analysis..

HEPATITIS C VACCINE

Hepatitis C virus is responsible for over 300,000 deaths per year world wide and in Australia causes 10,000 new cases each year. A vaccine t..

HEPATITIS C VACCINES

Hepatitis C is one of the most common notifiable infectious diseases in Australia with 200,000 infected individuals and 10,000 new infection..

Grants

Awarded by Australian Government

Funding Acknowledgements

This work was supported by research grants from the National Health and Medical Research Council (NHMRC) of Australia (Project grant APP1060436), Australian Center for HIV and Hepatitis Virology (ACH2), Commonwealth Department of Health and Aged Care, Australia; Australia-India Biotechnology Research Fund (BF040005), Department of Innovation and Industry, Australian Commonwealth Government. J. Torresi is supported by an NHMRC Practitioner Fellowship (APP1060433) and Eric Gowans by a NHMRC Senior Research Fellow award (Grant number 543139) and Stuart Ralph by a NHMRC Career Development Fellowship (APP1062504). The authors have no conflicts of interest to declare.